TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35210348
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of intravenous TXA administered intraoperatively
Study: 35210348
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) administered intraoperatively
Study: 33490018
Drug: HPHB intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HPHB intervention (a combination of health and parenting intervention augmenting routine ultrasound)
Study: 33284796
Drug: Normal (0.011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal (0.011 ml supplement/kg bodyweight)
Study: 33284796
Drug: High (0.063
Approvals — FDA: no, EMA: no, PMDA: no
Description: High (0.063 ml supplement/kg bodyweight)
Study: 33158717
Drug: Shufeng Jiedu
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shufeng Jiedu capsules (SFJDC) added to standard antiviral therapy (AVD)
Study: 33158717
Drug: Shufeng Jiedu
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shufeng Jiedu capsules (SFJDC)
Study: 35189953
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg/day for 10 weeks
Study: 32718816
Drug: RSVΔG vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVΔG vaccine (6.5 log10 CCID50)
Study: 37591656
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement treatment (HRT)
Study: 36495282
Drug: pFMI (90-µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pFMI (90-µg)
Study: 34455726
Drug: Lettuce seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lettuce seed syrup (5 mL twice daily)
Study: 34455726
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (5 mL twice daily)
Study: 32910478
Drug: Pembrolizumab administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab administered after CRT (arm 1)
Study: 32910478
Drug: Pembrolizumab administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab administered during CRT (arm 2)
Study: 34476445
Drug: Improved atraumatic
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved atraumatic restorative treatment (ART) with high-intensity glass ionomer cement
Study: 34476445
Drug: Conventional cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cavity preparation and composite resin filling (Control)
Study: 34767321
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G benzathine injections every 4 weeks for 2 years
Study: 36482520
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of glucosyl hesperidin per day
Study: 36482520
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of glucosyl hesperidin per day
Study: 32739495
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Anakinra (100 mg daily for 14 days), Pentoxifylline (400 mg three times a day for 28 days), and Zinc sulfate (220 mg orally once daily for 6 months)
Study: 32739495
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy including Methylprednisolone (32 mg orally once daily for 28 days)
Study: 32365232
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment rules (ITRs) using information from electronic health records (EHRs)
Study: 35432984
Drug: Colchicine add
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine add on treatment (1 mg daily for 7 days, then 0.5 mg daily for another 7 days)
Study: 35432984
Drug: Colchicine add
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine add on treatment
Study: 35765796
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment
Study: 32816626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of olive fruit extract (7.5 mg HT) and almond skin extracts (210 mg ASPs)
Study: 32356027
Drug: Vaginal probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal probiotic gel with L. plantarum YUN‐V2.0, L. pentosus YUN‐V1.0 and L. rhamnosus YUN‐S1.0 for 10 consecutive days
Study: 32356027
Drug: Vaginal probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal probiotic gel
Study: 32356027
Drug: Women needing
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women needing rescue treatment
Study: 34218922
Drug: Mixed tocopherols
Normalized name: vitamin E (as mixed tocopherols)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed tocopherols (TMIX) at 0, 5, 10, or 15 mg/kg of BW daily
Study: 36354032
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose mRNA-1273 (100 μg)
Study: 36354032
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose mRNA-1273 (2×100 μg)
Study: 36354032
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil discontinuation (mycophenolate mofetil-)
Study: 36354032
Drug: Local adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local adverse events after single and double dose mRNA-1273
Study: 33245043
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (mometasone furoate 0.1%) plus dummy narrowband ultraviolet B light
Study: 33245043
Drug: Narrowband ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband ultraviolet B light (plus placebo topical corticosteroids)
Study: 33245043
Drug: Combination (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (topical corticosteroids plus narrowband ultraviolet B light)
Study: 35122097
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of MCTs at breakfast
Study: 35122097
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of MCTs at dinnertime (positive control group)
Study: 32232954
Drug: Family focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family focused therapy for individuals at CHR (6 months)
Study: 32232954
Drug: Family psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family psychoeducational treatment (6 months)
Study: 32232954
Drug: Matched controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched controls (no specific treatment mentioned)
Study: 35015247
Drug: Asynchronous binocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asynchronous binocular treatment using 3D movies with amblyopic eye stimulated first for 10.5 hours over <3 weeks
Study: 35015247
Drug: Asynchronous binocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asynchronous binocular treatment
Study: 35900031
Drug: Test nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test nilotinib capsule (200 mg)
Study: 35900031
Drug: Reference nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference nilotinib capsule (200 mg)
Study: 33000503
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg every 2 weeks (Q2W) plus topical corticosteroids (TCS) as needed
Study: 32398441
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with 1.0 ppm DEX (1.8 μg)
Study: 32398441
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with 2.0 ppm DEX (3.6 μg)
Study: 32398441
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with 1:80,000 adrenaline (22.5 μg)
Study: 34087418
Drug: Glycopyrrolate bolus
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate bolus (0.4 mg IV)
Study: 34087418
Drug: Titrated glycopyrrolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated glycopyrrolate (0.01 mg IV every 3 min as needed)
Study: 34406656
Drug: Add-on cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on cannabidiol (CBD) titrated from 2.5 to 20 mg/kg/day, with potential increase to 30 mg/kg/day based on response and tolerance.
Study: 34406656
Drug: Add-on cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on cannabidiol (CBD) treatment
Study: 34794220
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus S‐1 (intravenous infusion of irinotecan 160 mg/m(2) on day 1 and oral S‐1 80‐120 mg on days 1‐10, repeated every 14 days)
Study: 32183057
Drug: Total protein
Normalized name: Total Protein Reagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total protein intake of 1 g·Kg−1·d−1 in week 2
Study: 34001723
Drug: Aprocitentan (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan (dual endothelin-receptor antagonist)
Study: 34001723
Drug: Moderately dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately dosed angiotensin-converting enzyme inhibitor
Study: 34750747
Drug: PPV-guided fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV-guided fluid therapy
Study: 34750747
Drug: CVP-guided fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVP-guided fluid therapy
Study: 34019245
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus platinum-based chemotherapy
Study: 34019245
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus platinum-based chemotherapy with PD-L1 expression of at least 5%
Study: 35007480
Drug: Nicotine-replacement therapies
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine-replacement therapies (NRT)
Study: 32534843
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg preoperatively
Study: 34701521
Drug: HA-IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-IMRT with memantine for salvage treatment in MRI surveillance group
Study: 33663100
Drug: Edaravone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone treatment on top of conventional treatment
Study: 34918875
Drug: Metopimazine (MPZ)
Normalized name: metopimazine
DrugBank: Metopimazine (DB13591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopimazine (MPZ) 60 mg
Study: 32981872
Drug: Decision making
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decision making by oral and maxillofacial surgeons (OMFSs)
Study: 34863618
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with vaccine deliberation and reluctance
Study: 34863618
Drug: Trend in
Normalized name: TITANIUM DIOXIDE 24 mg in 1 mL / ZINC OXIDE 58.2 mg in 1 mL TOPICAL CREAM [TRENDY JOHN SPF-32 Sheer Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trend in vaccine acceptance
Study: 35227528
Drug: Fiber-reinforced glass-ionomer
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-reinforced glass-ionomer cement (GIC) with adhesive treatment
Study: 35227528
Drug: Fiber-reinforced glass-ionomer
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-reinforced glass-ionomer cement (GIC) without adhesive treatment
Study: 35227528
Drug: Conventional glass-ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glass-ionomer cement (GIC) with adhesive treatment
Study: 35227528
Drug: Resin-modified glass-ionomer
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin-modified glass-ionomer cement (GIC) with adhesive treatment
Study: 35227528
Drug: Conventional glass-ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glass-ionomer cement (GIC) without adhesive treatment
Study: 35227528
Drug: Resin-modified glass-ionomer
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin-modified glass-ionomer cement (GIC) without adhesive treatment
Study: 35753316
Drug: Fractional doses
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional doses of RTS,S/AS01E (Fx012-14)
Study: 35753316
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (control group)
Study: 35753316
Drug: Full doses
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full doses of RTS,S/AS01E (R012-20)
Study: 35753316
Drug: Full doses
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full doses of RTS,S/AS01E (R012-14)
Study: 35753316
Drug: Fractional doses
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional doses of RTS,S/AS01E (Fx017-20)
Study: 32052032
Drug: Vehicle (rate-matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (rate-matched infusion)
Study: 36159932
Drug: Jin's three-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin's three-needle therapy (JTNT)
Study: 35788240
Drug: Cognitive Functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Functional Therapy (CFT) intervention, 5 to 7 sessions based on clinical progression.
Study: 32829703
Drug: Mumps-specific IgG
Normalized name: mumps virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mumps-specific IgG antibody testing using Enzygnost anti-parotitis IgG enzyme immunoassay
Study: 34783839
Drug: Background medication-based
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background medication-based individualized comparator (enalapril, valsartan, or placebo)
Study: 34783839
Drug: Background medication-based
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background medication-based individualized comparator
Study: 33044196
Drug: Active antidepressants
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antidepressants (fluoxetine, duloxetine, paroxetine, sertraline)
Study: 33938432
Drug: Combination serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination serum containing galactomyces ferment filtrate (GFF), dexpanthenol, and Centella asiatica, administered as three drops twice daily for 8 weeks.
Study: 33938432
Drug: Combination serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination serum containing GFF, dexpanthenol, and C. asiatica
Study: 36115638
Drug: Emotion Regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion Regulation Therapy for Caregivers (ERT-C)
Study: 36115638
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Caregivers (CBT-C)
Study: 34535197
Drug: TPX-100 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPX-100 (200 mg)
Study: 34414904
Drug: Resveratrol 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 500 mg a day with meloxicam 15 mg a day for 90 days
Study: 34414904
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with meloxicam 15 mg a day for 90 days
Study: 32245343
Drug: Median Urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median Urinary Iodine Concentration (MUI) measured in 1997, 1999, 2011, 2014, and 2017 with values of 228 µg/L, 214 µg/L, 1826 µg/L, 171 µg/L, and 183 µg/L respectively.
Study: 32245343
Drug: Median Thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median Thyroid Volume (MTvol) measured in 1997, 1999, 2011, 2014, and 2017 with values of 2.9 mL, 1.2 mL, 2.4 mL, 1.0 mL, and 1.8 mL, and 2.8 mL respectively.
Study: 35751161
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) at a daily dose of 600 mg orally in combination with other antiretrovirals (ARVs)
Study: 34567245
Drug: Secondary cytoreduction
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreduction and HIPEC (Cisplatin 75 mg/m2 43°C over 60 minutes)
Study: 33189262
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (BBP, MBP, HAL)
Study: 39718172
Drug: Monthly sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine-pyrimethamine
Study: 36090567
Drug: 80:40 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80:40 group (80 mg/kg/day ARA and 40 mg/kg/day DHA)
Study: 36090567
Drug: 120:60 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120:60 group (120 mg/kg/day ARA and 60 mg/kg/day DHA)
Study: 34609956
Drug: Asynchronous Video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asynchronous Video Observed Treatment (aVOT)
Study: 36385690
Drug: Nitrate containing
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate containing beetroot juice (400 mg daily)
Study: 36385690
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg daily)
Study: 32293830
Drug: Tetris and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetris and therapy (EMDR)
Study: 32293830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (therapy only - EMDR)
Study: 36449490
Drug: Real data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real data example regarding tablet absorption rate and extent
Study: 32926850
Drug: 15% dextrose
Normalized name: Clinimix Sulfite Free, Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% dextrose injection (D15W)
Study: 36125874
Drug: Group F
Normalized name: Prostaglandin group F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group F (ferrule preparation)
Study: 33154023
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with 16,000 IU of calcifediol per week
Study: 33154023
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to usual asthma treatment
Study: 32043561
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) behavioral intervention
Study: 35807854
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of whey protein microgel
Study: 35807854
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg mulberry leaf extract with a complete 510 kcal meal
Study: 33877019
Drug: Intravenous urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urokinase
Study: 33574437
Drug: Midazolam intravenous
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam intravenous sedation
Study: 32085836
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg S44819 twice a day
Study: 32085836
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg S44819 twice a day
Study: 36174812
Drug: Standard boric
Normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard boric acid solution
Study: 32857445
Drug: Varenicline directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline directly observed therapy (DOT)
Study: 32857445
Drug: Varenicline self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline self-administered therapy (SAT)
Study: 35465733
Drug: trastuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab + chemotherapy (eribuline, capecitabine, or vinorelbine)
Study: 35788754
Drug: AI-based ultra-low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI-based ultra-low-dose contrast medium (ULDCM)
Study: 35788754
Drug: Low-dose contrast
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose contrast medium (LDCM)
Study: 35788754
Drug: Ultra-low-dose contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose contrast medium (ULDCM)
Study: 32212508
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of Shuxuetong (SXT)
Study: 35045869
Drug: Meclofenamate (MFA)
Normalized name: meclofenamate
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate (MFA) combined with standard dose Temozolomide (TMZ)
Study: 35045869
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose Temozolomide (TMZ)
Study: 34661548
Drug: Tablet PC
Normalized name: PCS-499
DrugBank: PCS-499 (DB15122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet PC
Study: 34661548
Drug: Tablet PC
Normalized name: PCS-499
DrugBank: PCS-499 (DB15122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet PC and Smart Glasses
Study: 32703613
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group (unplugged pulsed 30 minutes of shortwave therapy)
Study: 32730628
Drug: iv acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv acetaminophen
Study: 35371287
Drug: CNHM model
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNHM model during bladder perfusion treatment